Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice

Tumori

Volumn 86, Issue 2, 2000, Pages 157-162

  Abdel Wahab, Mohamed H ^a   Akoul, El Sayed E M S ^a   Abdel Aziz, Abdel Aziz H ^a  

^a Al Azhar University   (Egypt)

Author keywords

Doxorubicin; EAC cells; Melatonin; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; MALONALDEHYDE; MELATONIN; OXYGEN RADICAL; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; EHRLICH ASCITES TUMOR; EXPERIMENTAL NEOPLASM; MOUSE; NONHUMAN; SURVIVAL RATE;

EID: 0342803640     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160008600210     Document Type: Article

References (40)

1. al-Herbi M.M., al-Gharably N.M., al-Shabanah O.A., al-Bekairi A.M., Osman A.M., Tawfik H.N.: Prevention of Dox-induced myocardial and haematological toxicities in rats by iron chelator desferrioxamine. Cancer Chemother. Pharmacol., 31: 200-204, 1992.
2. Bachur N.R., Gordon S.L., Gee M.V., Kon H.: NADPH-cytochrome P450 reductase activation of quinone anticancer agents to free radicals. Proc. Natl. Acad. Sci. USA, 76: 954-957, 1997.
3. Blask D.E., Leadem C.A.: Neuroendocrine aspects of neoplastic growth, a review. Neuroendocrinol. Lett., 2: 63-69, 1987.
4. Cos S., Blask D.E., Lemus-Wilson A., Hill A.B.: Effects of melatonin on cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells. J. Pineal Res., 17: 25-32, 1991.
5. Cos S., Blask D.E.: Melatonin modulates growth factor activity in McF-7 human breast cancer cells. J. Pineal Res., 17: 25-32, 1994.
6. Doroshow J.H.: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res., 43: 460-472. 1983.
7. Ellman G.L.: Tissue sulfhydryl groups. Arch. Biochem. Biophys., 74: 214-226, 1959.
8. Gupta M., Singal P.K.: Time course of structure, function and metabolic changes due to an exogenous source of oxygen metabolites in rat heart. Can. J. Physiol. Pharmacol., 67: 1549-1559, 1989.
9. Gustafson D.L., Swanson J.D., Pritsos C.A.: Modulation of glutathione and glutathione dependent antioxidant enzymes in mouse heart following Dox therapy. Free Rad. Res. Comms., 19: 111-120. 1993.
10. Halliwell B., Gutteridge J.M.C.: Oxygen free radicals in biology and medicine. Clarendon Press, Oxford, 1991.
11. Hill S.M., Spriggs L.L., Simon M.A., Muraoka H., Blask D.E.: Melatonin inhibition of human breast cancer cells linked to the estrogen response system. Cancer Lett., 64: 249-252, 1992.
12. Hilchcock-Bryan S., Gelber R.D., Cassady J.R., Sallan S.E.: The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med. Pediatr. Oncol., 14: 211-215, 1986.
13. Kalyanaraman B., Morehouse K.M., Mason R.P.: An electron paramagnetic resonance study of the interactions between the adriamycin semiquinone, hydrogen peroxide, iron-chelators and radical scavengers. Arch. Biochem. Biophys., 286: 164, 1991.
14. Kothari A., Borges A., Ingle, A., Kothari L.: Combination of melatonin and tamoxifen, as a chemoprophylaxis against N-nitrose-N-methylurea-induced rat mammary tumors. Cancer Lett., 111: 59-66, 1997.
15. Krivit W.: Adriamycin cardiotoxicity amelioration by alpha-tocopherol. Am. J. Pediatr. Hematol. Oncol., 1: 151-153. 1979.
16. Lazzarino G., Vida A.R., Mulieri L., Ratitio G., Marvelli I.: Prevention by fructos-1,6-bisphosphate of cardiac damage induced in mice by subchronic Dox treatment. Cancer Res., 47: 6511-6516, 1987.
17. Lissoni P., Tancini G., Barni S., Paolorossi F., Ardizzoia A., Conti A., Maestroni G.: Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support. Care Cancer, 5: 126-129, 1997.
18. Lowry O.M., Rosenbrough N.J., Farr A.L., Randall R.J.: Protein measurement with the folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
19. Mergens W.J., Bhagavan H.N.: Alpha-tocopherols (vitamin E). In: Nutrition and cancer prevention, Moon T.E. and Micazzi M.S. (Eds.), pp. 305-340, Dekker, New York, 1989.
20. Mimnaugh E.G., Trush M.A., Bhatrnagar M., Gram T.E.: Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem. Pharmacol., 34: 847-856, 1985.
21. Minami M., Yoshikawa H.: A simplified assay method of superoxide dismutase activity for clinical use. Clin. Chem. Acta, 92: 337, 1979.
22. Mirvish S.S.: Effects of vitamins C and E on N-nitrose compound formation, carcinogenesis, and cancer. Cancer (Philadelphia), 58: 1842-1850, 1986.
23. Myers C.E., Chabner B.A.: Anthracyclines, In: Cancer chemotherapy: Principles and practice, Chabner B.A. and Collins J.M. (Eds.), pp. 356-381, J.B. Lippincott Co., Philadelphia, 1990.
24. Myers C.E., McGuire W.P., Liss R.H., Ifrim I., Grotzinger K., Young R.C.: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science, 197: 165-167, 1977.
25. Nakamura Y., Othtaki S., Makino R., Tanaka T., Ishimura, Y: Superoxide anion in the initial product in the hydrogen peroxide formation catalyzed by NADPH oxidase in porcine thyroid plasma membrane. J. Biol. Chem., 264: 4759-4761, 1989.
26. Odom A.L., Hatwing C.A., Stanley J.S. Benson A.M.: Biochemical determinants of adriamycin toxicity in mouse liver, heart and intestine. Biochem. Pharmacol., 43: 831-836, 1992.
27. Panzer A., Viljoen M.: The validity of melatonin as an oncostatic agent. J. Pineal Res., 22: 184-202, 1997.
28. Reiter R.J.: The pineal and its hormones in the control of reproduction in mammals. Endocr. Rev., 12: 109-131, 1980.
29. Reiter R.J., Melchirri D., Sewerynek E.: A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal. Res., 18: 1-11, 1995.
30. Ripoll E.A., Rama B.N., Webber M.M.: Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. J. Urol., 136: 529-531, 1986.
31. Rose D.P., Noonan J.: Influence of prolactin and growth hormone on rat mammary tumors induced by n-nitrosomethylurea. Cancer Res., 42: 35-39, 1989.
32. Samuel L.: Dox-induced cardiotoxicity. Postgrad. Med. J., 71: 318, 1995.
33. Sehested M., Jensen P.B., Sorensen B.S., Holm B., Friche E., Demant E.J.: Antagonistic effect of ICRF-187 on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs, daunorubicin and etoposide (VP-16). Biochem. Pharmacol., 46: 389-393, 1993.
34. Speyer J.L., Green M.D., Kramer E., Rey M., Sanger J., Ward C.: Protective effect of the bispiperazinedione and ICRF-187 against doxorubicin-induced cardiotoxicity in women with advanced breast cancer. NEJM, 319: 745-752. 1988.
35. Tan D.X., Chen L.D. Poeggeler B., Reiter R.J.: Melatonin: A potent endogenous hydroxyl radical scavenger. Endocr. J., 1: 57-60, 1993.
36. Tong J., Ganguly P.K., Singal P.K.: Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am. J. Physiol., 260: H909-H916, 1991.
37. Uchiyama, M., Mihara, M.: Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem., 86: 271-278, 1978.
38. Vanderveen E., Vanderveen J.: Vitamins and other nutrients. In: Remington's pharmaceutical sciences, 18th edition, Vanderveen E. and Vanderveen J. (Eds.), pp. 1008-1022. Mack Publishing Company, Pennsylvania, 1990.
39. Vora J., Khaw B.A., Narula J., Boroujerdi M.: Protective effect of butylated hydroxyanisole on adriamycin-induced cardiotoxicity. J. Pharm. Pharmacol., 48: 940-944, 1996.
40. Welsch C.W.: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas, a review and tribute to Charles Benton Huggins. Cancer Res., 45: 3415-3443, 1985.